You are here

  • Home
  • Archive
  • Volume 77, Issue 6
  • Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

Article metrics

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

 

Online download statistics by month:

Online download statistics by month: March 2018 to March 2024

AbstractFullPdf
Mar 201816741701721
Apr 201822412290761
May 201816221650524
Jun 201810661076343
Jul 2018702701255
Aug 2018655655257
Sep 2018546546183
Oct 2018612612203
Nov 2018477477205
Dec 2018412412126
Jan 2019464457166
Feb 2019418417134
Mar 2019532533161
Apr 2019474474152
May 2019442442142
Jun 2019396395141
Jul 2019557541179
Aug 2019506501284
Sep 2019436431218
Oct 2019552529307
Nov 2019519502294
Dec 2019386376221
Jan 2020388381238
Feb 2020375358212
Mar 2020427395244
Apr 2020406396229
May 2020392375246
Jun 2020365349223
Jul 2020356341202
Aug 2020351336159
Sep 2020286282109
Oct 2020332314149
Nov 2020275262120
Dec 202030028990
Jan 2021279267151
Feb 2021341329130
Mar 2021290273123
Apr 2021261241140
May 2021284277150
Jun 2021237220116
Jul 2021271257116
Aug 2021305293126
Sep 2021339316119
Oct 2021362350169
Nov 2021304284127
Dec 202123621772
Jan 2022371367159
Feb 202224223296
Mar 2022376368142
Apr 2022325309130
May 2022375367150
Jun 2022390370125
Jul 202229428695
Aug 2022337340108
Sep 2022316308119
Oct 202224825175
Nov 202223422794
Dec 202216615656
Jan 202323221287
Feb 202326726078
Mar 2023454445129
Apr 2023269263107
May 2023257248101
Jun 202329728796
Jul 202322621997
Aug 202322722494
Sep 202323822290
Oct 202335134591
Nov 2023625558102
Dec 202327527371
Jan 2024206196126
Feb 202432330692
Mar 2024388386115
Total317603114512562